Cellosaurus OE19 (CVCL_1622)

Cell line name OE19
Synonyms OE-19; JROECL 19; JROECL19; OEC19
Accession CVCL_1622
Resource Identification Initiative To cite this cell line use: OE19 (RRID:CVCL_1622)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Characteristics: Contains a 100 fold amplification of ERBB2 (PubMed=15511476).
Doubling time: ~50-60 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Esophageal adenocarcinoma (NCIt: C4025)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; ECACC; PubMed=20075370; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,13
D13S3179,11
D16S53912,13
D18S5112,13 (PubMed=20075370)
12 (PubMed=25877200)
D19S43313
D21S1130
D2S133818,19
D3S135815,18
D5S81811,14
D7S8208
D8S117913,15
FGA23,26
Penta D9
Penta E5,8
TH018,9
TPOX8
vWA16,17 (Cosmic-CLP; ECACC)
16,17,18 (DSMZ; PubMed=20075370; PubMed=25877200)
Web pages http://tcpaportal.org/mclp/
http://www.phe-culturecollections.org.uk/media/115878/oe19-cell-line-profile.pdf
Publications

PubMed=9010035; DOI=10.1038/bjc.1997.42
Rockett J.C., Larkin K., Darnton S.J., Morris A.G., Matthews H.R.
Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization.
Br. J. Cancer 75:258-263(1997)

PubMed=15511476; DOI=10.1016/j.athoracsur.2004.05.037
Dahlberg P.S., Jacobson B.A., Dahal G., Fink J.M., Kratzke R.A., Maddaus M.A., Ferrin L.J.
ERBB2 amplifications in esophageal adenocarcinoma.
Ann. Thorac. Surg. 78:1790-1800(2004)

PubMed=16364037; DOI=10.1111/j.1442-2050.2006.00530.x
Su M., Chin S.-F., Li X.-Y., Edwards P., Caldas C., Fitzgerald R.C.
Comparative genomic hybridization of esophageal adenocarcinoma and squamous cell carcinoma cell lines.
Dis. Esophagus 19:10-14(2006)

PubMed=20075370; DOI=10.1093/jnci/djp499
Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P., Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K., Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H., Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
J. Natl. Cancer Inst. 102:271-274(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24083764; DOI=10.7314/APJCP.2013.14.8.4891
Li J.-C., Liu D., Yang Y., Wang X.-Y., Pan D.-L., Qiu Z.-D., Su Y., Pan J.-J.
Growth, clonability, and radiation resistance of esophageal carcinoma-derived stem-like cells.
Asian Pac. J. Cancer Prev. 14:4891-4896(2013)

PubMed=25070024; DOI=10.1007/s00423-014-1235-1
Drenckhan A., Grob T., Dupree A., Dohrmann T., Mann O., Izbicki J.R., Gros S.J.
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.
Langenbecks Arch. Surg. 399:879-888(2014)

PubMed=23795680; DOI=10.1111/dote.12095
Boonstra J.J., Tilanus H.W., Dinjens W.N.M.
Translational research on esophageal adenocarcinoma: from cell line to clinic.
Dis. Esophagus 28:90-96(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections DSMZ; ACC-700
ECACC; 96071721
Cell line databases/resources CLDB; cl3761
CCLE; OE19_OESOPHAGUS
Cosmic-CLP; 910079
GDSC; 910079
IGRhCellID; OE19
LINCS_LDP; LCL-1796
Ontologies CLO; CLO_0008238
EFO; EFO_0002308
Biological sample resources BioSample; SAMN03471032
Chemistry resources ChEMBL-Cells; CHEMBL3308462
ChEMBL-Targets; CHEMBL1075555
Gene expression databases GEO; GSM827301
GEO; GSM887475
GEO; GSM888555
GEO; GSM1264050
GEO; GSM1264051
GEO; GSM1264052
GEO; GSM1264053
GEO; GSM1264054
GEO; GSM1264092
GEO; GSM1264093
GEO; GSM1264094
GEO; GSM1264095
GEO; GSM1264096
GEO; GSM1670302
Polymorphism and mutation databases Cosmic; 871232
Cosmic; 910079
Cosmic; 978854
Cosmic; 997860
Cosmic; 1175878
Cosmic; 1599342
Cosmic; 1618819
Cosmic; 1995600